| Screening | Baseline visita | Treatment | End of treatment (EOT)g | EOT to end of study | ||||
---|---|---|---|---|---|---|---|---|---|
Weeks (w) | –2 w ~  –1 d | 0 | 1 w | 2 w | 4 w | 8 w | 12 w ~ (every 4w) | 40 w ~  52 w | ~  24 months (every 2 months) |
Visit window | NA | NA | ± 4 days | ± 4 days | ±1w | ±2w | ±2 w | ±2 w | ±2 w |
Consent | X | Â | Â | Â | Â | Â | Â | Â | Â |
Randomization | Â | X | Â | Â | Â | Â | Â | Â | Â |
Medical history | X | Â | Â | Â | Â | Â | Â | Â | Â |
Physical exam | X | Â | X | X | X | X | X | X g | Â |
Neurological exam | X | Â | X | X | X | X | X | X g | Â |
Sputum AFB smear | X e | X e | X | X | X | X | X | X | X |
TB culture (solid) | X e | X e | X | X | X | X | X | X | X |
TB culture (liquid) | X e | X e | X | X | X | X | X | X | X |
Genotypic DST | If available | ||||||||
Phenotypic DSTb | With first/reverted cultured Mycobacterium tuberculosis | ||||||||
Resistance test | If needed (for linezolid, delamanid) | ||||||||
CXR | X e | X e | X h | X h | X | X | X | X | X |
Chemistry, electrolytes | X e | X e | X | X | X | X | X | X g | Â |
Complete blood count | X e | X e | X | X | X | X | X | X g | Â |
ECG | X e | X e | X | X | X | X | X | X g | Â |
Urine HCGc | X | X | X | X | X | X | X | X g | Â |
HIV, HBVd | Â | X e | Â | Â | Â | Â | Â | Â | Â |
Optic test | X | X | X | X | X | X | X | X g | Â |
Compliance of drug intake | Â | Â | X | X | X | X | X | X g | Â |
Adverse drug reaction | Â | Â | X | X | X | X | X | X g | Â |
Other medicationf | X | X | X | X | X | X | X | X g | Â |